These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36972373)

  • 61. The year in cardiovascular medicine 2021: diabetes and metabolic disorders.
    Cosentino F; Bhatt DL; Marx N; Verma S
    Eur Heart J; 2022 Jan; 43(4):263-270. PubMed ID: 34974614
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease.
    Yagyu H; Shimano H
    J Diabetes Investig; 2022 Sep; 13(9):1472-1488. PubMed ID: 35638331
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.
    Shehadeh N; Raz I; Nakhleh A
    Cardiovasc Diabetol; 2018 Aug; 17(1):117. PubMed ID: 30134893
    [No Abstract]   [Full Text] [Related]  

  • 65. Type 2 diabetes mellitus and cardiovascular disease: focus on the effect of antihyperglycemic treatments on cardiovascular outcomes.
    Choxi R; Roy S; Stamatouli A; Mayer SB; Jovin IS
    Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):187-199. PubMed ID: 32306789
    [No Abstract]   [Full Text] [Related]  

  • 66. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
    Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.
    Caparrotta TM; Blackbourn LAK; McGurnaghan SJ; Chalmers J; Lindsay R; McCrimmon R; McKnight J; Wild S; Petrie JR; Philip S; McKeigue PM; Webb DJ; Sattar N; Colhoun HM;
    Diabetes Care; 2020 Sep; 43(9):2034-2041. PubMed ID: 32581068
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Making sense of newer treatment options for type 2 diabetes.
    Lee PC; Hare MJL; Bach LA
    Intern Med J; 2018 Jul; 48(7):762-769. PubMed ID: 29984503
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The present and future treatment of pediatric type 2 diabetes.
    Van Name MA; Guandalini C; Steffen A; Patel A; Tamborlane W
    Expert Rev Endocrinol Metab; 2018 Jul; 13(4):207-212. PubMed ID: 30063424
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes.
    Kalyani RR
    N Engl J Med; 2021 Apr; 384(13):1248-1260. PubMed ID: 33789013
    [No Abstract]   [Full Text] [Related]  

  • 72. Metformin and cardiorenal outcomes in diabetes: A reappraisal.
    Petrie JR; Rossing PR; Campbell IW
    Diabetes Obes Metab; 2020 Jun; 22(6):904-915. PubMed ID: 32009286
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
    D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
    Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A review on cardiovascular effects of newer hypoglycaemic medications.
    Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
    Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes.
    Jha KK; Adhikari R; Tasdighi E; Osuji N; Rajan T; Blaha MJ
    Curr Atheroscler Rep; 2022 Dec; 24(12):925-937. PubMed ID: 36422789
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cardiodiabetology: newer pharmacologic strategies for reducing cardiovascular disease risks.
    Wong ND
    Can J Physiol Pharmacol; 2022 Oct; 100(10):956-967. PubMed ID: 35772176
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile.
    Muzurović E; Mikhailidis DP
    Expert Opin Pharmacother; 2020 Dec; 21(17):2125-2135. PubMed ID: 32697112
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
    Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
    [TBL] [Abstract][Full Text] [Related]  

  • 80. What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes.
    Ferraro RA; Nass CM; Dudum R; Blumenthal RS; Sarkar S
    Am J Med; 2019 Sep; 132(9):1027-1031. PubMed ID: 30904510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.